ASO Bioanalysis Assay Development

About Nanovery

Nanovery is an early-stage biotech company developing a unique, enzyme-free diagnostic platform based on programmable DNA nanorobots. Its technology aims to directly and quantitatively detect short nucleic acid targets like ASOs, siRNAs, and miRNAs with minimal sample preparation and standard lab equipment. The company is initially targeting the research and bioanalysis market for RNA therapeutics, with a value proposition centered on simplicity, speed, and cost reduction compared to conventional methods like qPCR. As a private, likely pre-revenue entity, Nanovery is focused on assay development services and platform validation.